#London #United Kingdom #Citius Pharmaceuticals #LYMPHIR #Citius Oncology

Citius Pharmaceuticals Showcases Innovations at Jefferies Conference

Citius Pharmaceuticals, Inc. is making headlines as it prepares to participate in the prestigious Jefferies Global Healthcare Conference, scheduled from November 16 to 19, 2026, at the Waldorf Hilton in London. The conference is a significant event that attracts key players from the healthcare and biopharmaceutical sectors.

Leonard Mazur, the Chairman and CEO of Citius Pharma, will represent the company, engaging in one-on-one meetings to provide insights into Citius Pharma's business model and the latest advancements. This event presents a platform for the company to connect with investors and industry leaders, fostering relationships that could propel their innovative products into the market.

Citius Pharmaceuticals is known for its dedication to developing and commercializing first-in-class critical care products, emphasizing a commitment to addressing unmet medical needs. Among its noteworthy products is LYMPHIR® (denileukin diftitox-cxdl), a targeted immunotherapy now being commercialized by Citius's majority-owned subsidiary, Citius Oncology, Inc. This groundbreaking therapy was approved for use in adults suffering from relapsed or refractory Stage I-III CTCL (cutaneous T-cell lymphoma), marking a significant milestone in targeted cancer treatment.

The launch of LYMPHIR back in December 2025 positioned Citius Pharma as a key player in the oncology sector, with a market estimated to exceed $400 million. Aimed to improve outcomes for patients who have not responded to existing treatments, LYMPHIR demonstrates the company's commitment to innovation and patient care.

In addition to LYMPHIR, Citius Pharmaceuticals is advancing its late-stage pipeline, which includes Mino-Lok®, an innovative catheter lock solution designed to address catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation aimed at relieving hemorrhoids. Mino-Lok has shown promising results in its Phase 3 trial, successfully meeting primary and secondary endpoints, while preparations for ongoing FDA discussions regarding both Mino-Lok and Halo-Lido are in progress.

Citius Pharmaceuticals aims to engage the investment community at the Jefferies Conference, providing detailed insights into its pipeline and discussing strategic plans moving forward. The conference format allows for personalized engagement between participants, making it an ideal setting for Citius Pharma to articulate its vision and value proposition.

As the biopharmaceutical landscape continues to evolve, Citius Pharmaceuticals proves to be an exciting company to watch. Their innovative approaches to critical care products not only pave the way for new treatment protocols but also highlight the importance of targeted therapies in modern medicine. The Jefferies Global Healthcare Conference is a perfect venue for Citius to demonstrate its commitment to improving patient health outcomes and to further solidify its position as a leader in the biopharmaceutical industry.

For further updates and detailed information about Citius Pharmaceuticals and its product offerings, interested individuals can visit the company’s official website at www.citiuspharma.com. Additionally, more about Citius Oncology can be found at www.citiusonc.com to explore their innovative oncology therapies.

The participation of Citius Pharmaceuticals at the Jefferies Global Healthcare Conference represents a strategic opportunity for the company to showcase its achievements and vision for the future. Investors and stakeholders are keenly awaiting the insights that will be shared during this notable event.